Akshat Jain/Photo:
lluh.org
Apr 22, 2026, 07:40
Akshat Jain: WIL33 Study Advances Factor Prophylaxis in Children with von Willebrand Disease
Akshat Jain, Hematology Pediatric Workforce Task Force at American Society of Hematology, shared a post on LinkedIn:
”It was wonderful presenting our research on factor prophylaxis for Children with Von Willebrand Disease at the WFH 2026 congress.
How we treat VWD especially in young children remain undetermined in the absence of robust clinical trials and medications that always are late to arrive for pediatric indications.
Through the WIL33 study (7 country, 3 continents ) that I had the honor to lead for Octapharma this gap has been addressed and real world care can start to be defined to assist clinicians world over.”

Stay updated with Hemostasis Today.
-
Nov 15, 2026, 16:29Jean-Jacques Kiladjian: 20 Years of Interferon-Alpha Research in Myeloproliferative Neoplasms
-
Nov 15, 2026, 16:21Sukanto Paul: Why Platelet Transfusion Is Generally Avoided in TTP
-
Nov 15, 2026, 16:14Ahmad G. Alzahrani: Major Bleeding and Anticoagulant Reversal
-
Nov 15, 2026, 16:05Sabine Eichinger: Is Recurrence Risk After Provoked VTE Really Low?
-
Nov 15, 2026, 15:53Nicolas Schommer: The Seed and Soil Hypothesis of NET-Mediated Inflammation
-
Nov 15, 2026, 15:36Giovanni Merlino: Targeting LDL-C to Prevent Recurrent Stroke
-
Nov 15, 2026, 15:33Riitta Lassila: From Helsinki to ISTH 2027 Advancing Thrombosis Research
-
Nov 15, 2026, 15:30Andreas Calatzis: Can Protein C and Plasma Overcome Fibrinolysis Resistance in Sepsis?
-
Nov 15, 2026, 15:25Hussnain Javaid: Thalassaemia 2026 New Therapies Transforming UK Practice